Dr. Julius Chapiro
Radiologist
2 Podcasts on BackTable
Dr. Julius Chapiro is a radiologist and Associate Professor of Radiology and Biomedical Engineering at Yale School of Medicine in New Haven, Conneticut.
Learn from the experiences and expertise of Dr. Julius Chapiro and other leading voices in your specialty on the BackTable app.
Episode # 538 • 29 Apr 2025
Immunotherapy & TACE in HCC Treatment
There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.
This podcast is supported by an educational grant from Guerbet.
More from Dr. Julius Chapiro
Loading recent podcasts…
About
Dr. Chapiro is an Associate Professor in Radiology, Digestive Diseases (Hepatology) and in Biomedical Engineering, Principal Investigator of the Yale Interventional Oncology Research Lab and Director of the Center for Minimally Invasive Therapies. After graduating from the University of Leipzig and upon completion of his research thesis at the Justus-Liebig University in Giessen with summa cum laude, he served as a postdoctoral research fellow in interventional oncology at The Johns Hopkins Hospital and then as radiology resident at the Department of Radiology, Charité University Hospital in Berlin. He joined the Department of Radiology and Biomedical Imaging in 2016 as a research scientist and interventional radiology resident from Berlin, Germany.
Dr. Chapiro’s research focuses on developing new quantitative imaging biomarkers for the diagnosis, characterization, and therapeutic management of liver cancer. His translational research portfolio includes the development of novel embolic agents as well as the application of artificial intelligence solutions for the management of liver cancer. His basic research interest mainly focuses on developing new tools to characterize the tumor microenvironment and the immune system in the setting of loco-regional, image-guided therapies of liver cancer.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.